Congruence raises $39.5 million to advance small molecule corrector pipeline
Congruence Therapeutics has introduced the completion of a $39.5 million financing spherical to advance its portfolio of small molecule correctors to the clinic.
The portfolio contains applications focusing on melanocortin 4 receptor (MC4R)-deficient genetic weight problems, glucocerebrosidase 1 (GBA1)-mediated Parkinson’s illness and alpha-1 antitrypsin deficiency.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The financing was co-led by Dimension and OrbiMed, with further participation from Amplitude Ventures, BDC Capital’s Thrive Enterprise Fund, Driehaus, FSTQ, Investissement Quebec, Lumira and Silver Arc.
It would primarily fund the Section I/Ib examine of CGX-926, Congruence Therapeutics’ lead program for MC4R-deficient genetic weight problems, which can enroll each wholesome topics and sufferers.
Congruence Therapeutics additionally plans to finish investigational new drug (IND) actions for 2 growth candidates focusing on GBA1-mediated Parkinson’s illness and alpha-1 antitrypsin deficiency.
The corporate goals to submit Medical Trial Purposes (CTA)/IND functions for these applications in early 2027.
Co-founder and CEO of Congruence Therapeutics, Dr. Clarissa Desjardins, mentioned: “Our mission is to translate organic, chemical and structural protein insights into medicines that tackle ailments at their molecular origins.
“Along with CGX-926, we’re advancing a number of proprietary and collaborative applications. We thank our new and present traders for his or her continued assist.”
Dimension’s founder and managing accomplice Zavain Dar mentioned: “By leveraging cutting-edge molecular dynamics and machine studying, Congruence has constructed a best-in-class platform to unlock an thrilling modality of medication in small molecule correctors.”
Congruence continues its analysis collaboration, together with an expanded multi-target partnership with Ono Prescribed drugs in neurology, immunology and oncology.
One other collaboration entails drug discovery for a metabolic goal with a worldwide pharmaceutical firm.
The corporate’s Revenir computing platform analyzes dynamic protein states to foretell small molecule modulation, supporting the pipeline of genetically validated targets with unmet medical wants.
